A Retrospective Analysis of Patient-specific Factors on Voriconazole Clearance

Overview

Journal J Pharm Health Care Sci

Publisher Biomed Central

Specialty Pharmacology

Date 2016 Apr 21

PMID 27096102

Citations 30

Authors

Satoshi Dote

Maki Sawai

Ayumu Nozaki

Kazumasa Naruhashi

Yuka Kobayashi

Hirokazu Nakanishi

Affiliations

Soon will be listed here.

Abstract

Background: Voriconazole concentrations display a large variability, which cannot completely be explained by known factors. We investigated the relationships of voriconazole concentration with patient-specific variables and concomitant medication to identify clinical factors affecting voriconazole clearance.

Methods: A retrospective chart review of voriconazole trough concentration, laboratory data, and concomitant medication in patients was performed. The concentration/dose ratio (C/D-ratio) was assessed as a surrogate marker of total clearance by dividing voriconazole concentration by daily dose per kg of body weight.

Results: A total of 77 samples from 63 patients were obtained. In multiple linear regression analysis, increased C-reactive protein (CRP) level (p < 0.05) and decreased albumin (Alb) level (p < 0.05) were associated with significantly increased C/D-ratio of voriconazole, and coadministration with a glucocorticoid was associated with significantly (p < 0.05) decreased C/D-ratio of voriconazole (adjusted r (2) = 0.31). Regarding CRP and Alb, receiver operating characteristic curve analysis indicated that increased CRP level and decreased Alb level were significant predictors of toxic trough concentration of voriconazole. For CRP, area under the curve (AUC) and cutoff value were 0.71 (95 % confidence interval (CI), 0.57-0.86, p < 0.01) and 4.7 mg/dl, respectively. For Alb, AUC and cutoff value were 0.68 (95 % CI, 0.53-0.82, p < 0.05) and 2.7 g/dl, respectively. A significant difference was seen in voriconazole trough concentration between patients with hepatotoxicity and those without (5.69 μg/ml vs 3.0 μg/ml, p < 0.001).

Conclusion: Coadministration of glucocorticoid and inflammation, reflected by elevated CRP level and hypoalbuminemia, are associated with voriconazole clearance. We propose that early measurement of voriconazole concentration before the plateau phase will lead to avoidance of a toxic voriconazole level in patients with elevated CRP level and hypoalbuminemia, although further studies are needed to confirm our findings.

Citing Articles

Voriconazole in the treatment of pediatric patients with hematologic malignancies and invasive fungal infections: a real-world study.

Wu N, Cai L, Zhang Q, Fan Y, Lin Z Eur J Clin Microbiol Infect Dis. 2025; .

PMID: 40057934 DOI: 10.1007/s10096-025-05067-y.

Association of procalcitonin with voriconazole concentrations: a retrospective cohort study.

Zhou J, Xiong C, Chang Z, Yin Y, Su K, Zhang J BMC Infect Dis. 2024; 24(1):952.

PMID: 39256640 PMC: 11389108. DOI: 10.1186/s12879-024-09862-4.

Associated factors with voriconazole plasma concentration: a systematic review and meta-analysis.

Li X, Hu Q, Xu T Front Pharmacol. 2024; 15:1368274.

PMID: 39246651 PMC: 11377273. DOI: 10.3389/fphar.2024.1368274.

Renal Replacement Therapy as a New Indicator of Voriconazole Clearance in a Population Pharmacokinetic Analysis of Critically Ill Patients.

Wang Y, Ye Q, Li P, Huang L, Qi Z, Chen W Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931333 PMC: 11206427. DOI: 10.3390/ph17060665.

The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals.

Li G, Li Q, Zhang C, Yu Q, Li Q, Zhou X Front Genet. 2023; 14:1242711.

PMID: 37693307 PMC: 10484623. DOI: 10.3389/fgene.2023.1242711.

References

Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y . Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet. 2004; 18(1):48-70. DOI: 10.2133/dmpk.18.48. View

MARTIN P, Riley R, Back D, Owen A . Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br J Pharmacol. 2007; 153(4):805-19. PMC: 2259202. DOI: 10.1038/sj.bjp.0707601. View

van Wanrooy M, Span L, Rodgers M, van den Heuvel E, Uges D, van der Werf T . Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014; 58(12):7098-101. PMC: 4249508. DOI: 10.1128/AAC.03820-14. View

Naito T, Yamada T, Mino Y, Kawakami J . Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients. Clin Chim Acta. 2014; 441:127-32. DOI: 10.1016/j.cca.2014.12.024. View

Villikka K, Varis T, Backman J, Neuvonen P, Kivisto K . Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo. Eur J Clin Pharmacol. 2001; 57(6-7):457-60. DOI: 10.1007/s002280100340. View

Shimada T, Terada A, Yokogawa K, Kaneko H, Nomura M, Kaji K . Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation. 2002; 74(10):1419-24. DOI: 10.1097/00007890-200211270-00014. View

Hamada Y, Seto Y, Yago K, Kuroyama M . Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother. 2012; 18(4):501-7. DOI: 10.1007/s10156-011-0363-6. View

Zordoky B, El-Kadi A . Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr Drug Metab. 2009; 10(2):164-78. DOI: 10.2174/138920009787522151. View

Chen Y, Ferguson S, Negishi M, Goldstein J . Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol. 2003; 64(2):316-24. DOI: 10.1124/mol.64.2.316. View

10.

Geist M, Egerer G, Burhenne J, Riedel K, Weiss J, Mikus G . Steady-state pharmacokinetics and metabolism of voriconazole in patients. J Antimicrob Chemother. 2013; 68(11):2592-9. DOI: 10.1093/jac/dkt229. View

11.

Dolton M, McLachlan A . Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. Curr Opin Infect Dis. 2014; 27(6):493-500. DOI: 10.1097/QCO.0000000000000103. View

12.

Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S . Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013; 19(3):381-92. PMC: 3682092. DOI: 10.1007/s10156-013-0607-8. View

13.

Traunmuller F, Popovic M, Konz K, Smolle-Juttner F, Joukhadar C . Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology. 2011; 88(3-4):213-24. DOI: 10.1159/000331860. View

14.

Dolton M, Ray J, Chen S, Ng K, Pont L, McLachlan A . Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012; 56(9):4793-9. PMC: 3421881. DOI: 10.1128/AAC.00626-12. View

15.

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

16.

Suzuki Y, Tokimatsu I, Sato Y, Kawasaki K, Sato Y, Goto T . Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clin Chim Acta. 2013; 424:119-22. DOI: 10.1016/j.cca.2013.05.025. View

17.

Shi H, Yan J, Zhu W, Yang G, Tan Z, Wu W . Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur J Clin Pharmacol. 2010; 66(11):1131-6. PMC: 2957581. DOI: 10.1007/s00228-010-0869-3. View

18.

Lee S, Kim B, Nam W, Yoon S, Cho J, Shin S . Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2011; 52(2):195-203. DOI: 10.1177/0091270010395510. View

19.

Seyedmousavi S, Mouton J, Verweij P, Bruggemann R . Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther. 2013; 11(9):931-41. DOI: 10.1586/14787210.2013.826989. View

20.

Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y . Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009; 89(5):592-9. DOI: 10.1007/s12185-009-0296-3. View